Speaker Profile
PMWC LUMINARY AWARD
Ph.D., Distinguished Professor Emeritus of Metabolism and Endocrinology, UCSF
Biography
Dr. Jeff Bluestone is a Distinguished Emeritus Professor in the Diabetes Center at
UCSF and a managing director of Vie Ventures. He served in various other roles over 25
years at UCSF, including as a member of the faculty, Founding Director of the Diabetes Center,
and Executive Vice Chancellor and Provost. He is an international leader in the field of
immunotherapy and has published more than 500 papers focused on understanding the basic
processes that control T-cell activation and immune tolerance in autoimmunity, organ
transplantation and cancer. His research has led to the development of the first FDA-approved
drug that delays/prevents autoimmune Type 1 diabetes and the first FDA-approved checkpoint
inhibitor for the treatment of metastatic melanoma and other cancers. Dr. Bluestone was the
Founding Director of the Immune Tolerance Network and the Founding CEO of the Parker
Institute for Cancer Immunotherapy. Dr. Bluestone is a member of the National Academy of
Science, National Academy of Medicine, and American Academy of Arts and Sciences.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
